{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:33:55Z","timestamp":1789850035682,"version":"4.0.1"},"reference-count":29,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2024.0230","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T11:40:58Z","timestamp":1737632458000},"source":"Crossref","is-referenced-by-count":6,"title":["The management of chronic kidney disease not requiring renal replacement therapy in general practice"],"prefix":"10.3238","author":[{"given":"Simone","family":"Kiel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Negnal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Stracke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Fleig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin K.","family":"Kuhlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Chenot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"10.3238\/arztebl.m2024.0230_ref1","unstructured":"Deutsche Gesellschaft f\u00fcr Allgemeinmedizin und Familienmedizin (DEGAM) und Deutsche Gesellschaft f\u00fcr Nephrologie (DGfN). Versorgung von Patient*innen mit chronischer, nicht-nierenersatztherapiepflichtiger Nierenkrankheit in der Hausarztpraxis. Juni 2024. https:\/\/www.degam.de\/leitlinie-s3\u2013053\u2013048 (last accessed on 3 December 2024)."},{"key":"10.3238\/arztebl.m2024.0230_ref2","doi-asserted-by":"crossref","unstructured":"Girndt M, Trocchi P, Scheidt-Nave C, Markau S, Stang A: The prevalence of renal failure. Results from the German Health Interview and Examination Survey for Adults, 2008\u20132011 (DEGS1). Dtsch Arztebl Int 2016; 113: 85\u201391","DOI":"10.3238\/arztebl.2016.0085"},{"key":"10.3238\/arztebl.m2024.0230_ref3","doi-asserted-by":"crossref","unstructured":"Gergei I, Klotsche J, Woitas RP, et al.: Chronic kidney disease in primary care in Germany. J Public Health 2017; 25: 223\u201330","DOI":"10.1007\/s10389-016-0773-0"},{"key":"10.3238\/arztebl.m2024.0230_ref4","doi-asserted-by":"crossref","unstructured":"Hoffmann F, Boeschen D, D\u00f6rks M, Herget-Rosenthal S, Petersen J, Schmiemann G: Renal insufficiency and medication in nursing home residents\u2014a cross-sectional study (IMREN). Dtsch Arztebl Int 2016; 113: 92\u20138","DOI":"10.3238\/arztebl.2016.0092"},{"key":"10.3238\/arztebl.m2024.0230_ref5","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2024; 105: S117\u2013314."},{"key":"10.3238\/arztebl.m2024.0230_ref6","doi-asserted-by":"crossref","unstructured":"Levey AS, de Jong PE, Coresh J, et al.: The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report. Kidney Int 2011; 80: 17\u201328","DOI":"10.1038\/ki.2010.483"},{"key":"10.3238\/arztebl.m2024.0230_ref7","unstructured":"Institut f\u00fcr Qualit\u00e4tssicherung und Transparenz im Gesundheitswesen. Jahresbericht 2019 zur Qualit\u00e4t in der Dialyse: Erstellt im Auftrag des Gemeinsamen Bundesausschusses. 2020. www.g-ba.de\/downloads\/39-261-4568\/2020-11-20_QSD-RL_IQTIG-Jahresbericht-2019.pdf (last accessed on 18.11.2024)."},{"key":"10.3238\/arztebl.m2024.0230_ref8","doi-asserted-by":"crossref","unstructured":"Eckardt KU, Binet I, Groot K de, et al.: Nomenklatur f\u00fcr Nierenfunktion und Nierenkrankheiten\u2014Durch Pr\u00e4zision und Verst\u00e4ndlichkeit zu besserer Erfassung und Prognose. Dtsch Med Wochenschr 2022; 147: 1398\u2013406","DOI":"10.1055\/a-1908-5163"},{"key":"10.3238\/arztebl.m2024.0230_ref9","doi-asserted-by":"crossref","unstructured":"Weckmann GFC, Stracke S, Haase A, et al.: Diagnosis and management of non-dialysis chronic kidney disease in ambulatory care: a systematic review of clinical practice guidelines. BMC Nephrol 2018; 19: 258","DOI":"10.1186\/s12882-018-1048-5"},{"key":"10.3238\/arztebl.m2024.0230_ref10","unstructured":"National Institute for Health and Care Excellence. Chronic kidney disease: assessment and management. London 2021. NICE guideline. www.nice.org.uk\/guidance\/ng203 (last accessed on 18.11.2024)."},{"key":"10.3238\/arztebl.m2024.0230_ref11","unstructured":"Mainz A: Nicht sichtbare H\u00e4maturie (NSH): DEGAM S1-Handlungsempfehlungen. 2020. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/053\u2013028 (last accessed on 18.11.2024)."},{"key":"10.3238\/arztebl.m2024.0230_ref12","doi-asserted-by":"crossref","unstructured":"Grams ME, Brunskill NJ, Ballew SH, et al.: The kidney failure risk equation: evaluation of novel input variables including eGFR estimated using the CKD-EPI 2021 equation in 59 cohorts. J Am Soc Nephrol 2023;34: 482\u201394","DOI":"10.1681\/ASN.0000000000000050"},{"key":"10.3238\/arztebl.m2024.0230_ref13","doi-asserted-by":"crossref","unstructured":"Lennartz CS, Pickering JW, Seiler-Mu\u00dfler S, et al.: External validation of the kidney failure risk equation and re-calibration with addition of ultrasound parameters. Clin J Am Soc Nephrol 2016;11: 609\u201315","DOI":"10.2215\/CJN.08110715"},{"key":"10.3238\/arztebl.m2024.0230_ref14","doi-asserted-by":"crossref","unstructured":"Hundemer GL, Tangri N, Sood MM, et al. Performance of the kidney failure risk equation by disease etiology in advanced CKD. Clin J Am Soc Nephrol 2020; 15: 1424\u201332","DOI":"10.2215\/CJN.03940320"},{"key":"10.3238\/arztebl.m2024.0230_ref15","doi-asserted-by":"crossref","unstructured":"Gregorich M, Kammer M, Heinzel A, et al.: Development and validation of a prediction model for future estimated glomerular filtration rate in people with type 2 diabetes and chronic kidney disease. JAMA Netw Open 2023; 6: e231870","DOI":"10.1001\/jamanetworkopen.2023.1870"},{"key":"10.3238\/arztebl.m2024.0230_ref16","doi-asserted-by":"crossref","unstructured":"Zhang Y, He D, Zhang W, et al.: ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3\u20135: a network meta-analysis of randomised clinical trials. Drugs 2020; 80: 797\u2013811","DOI":"10.1007\/s40265-020-01290-3"},{"key":"10.3238\/arztebl.m2024.0230_ref17","doi-asserted-by":"crossref","unstructured":"European Society of Hypertension (ESH) (2023) ESH Guidelines for the Management of Arterial Hypertension. J Hypertens 2023; 41: 1874\u20132071","DOI":"10.1016\/j.hipert.2024.02.004"},{"key":"10.3238\/arztebl.m2024.0230_ref18","doi-asserted-by":"crossref","unstructured":"Matsushita K, Kaptoge S, Hageman SHJ, et al.: Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP. Eur J Prev Cardiol 2023; 30: 8\u201316","DOI":"10.1093\/eurheartj\/ehac544.2256"},{"key":"10.3238\/arztebl.m2024.0230_ref19","doi-asserted-by":"crossref","unstructured":"Tunnicliffe DJ, Palmer SC, Cashmore BA, et al.: HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2023; 11: CD007784","DOI":"10.1002\/14651858.CD007784.pub3"},{"key":"10.3238\/arztebl.m2024.0230_ref20","unstructured":"Arzneimittelkommission der deutschen \u00c4rzteschaft (Akd\u00c4): Medikament\u00f6se Cholesterinsenkung zur Vorbeugung kardiovaskul\u00e4rer Ereignisse. 2023. www.akdae.de\/fileadmin\/user_upload\/akdae\/Arzneimitteltherapie\/LF\/PDF\/Cholesterinsenkung.pdf (last accessed on 18.11.2024)."},{"key":"10.3238\/arztebl.m2024.0230_ref21","doi-asserted-by":"crossref","unstructured":"Natale P, Palmer SC, Saglimbene VM, et al.: Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev 2022; 2: CD008834","DOI":"10.1002\/14651858.CD008834.pub4"},{"key":"10.3238\/arztebl.m2024.0230_ref22","doi-asserted-by":"crossref","unstructured":"Ruospo M, Saglimbene VM, Palmer SC, et al.: Glucose targets for preventing diabetic kidney disease and its progression. Cochrane Database Syst Rev 2017; 6: CD010137","DOI":"10.1002\/14651858.CD010137.pub2"},{"key":"10.3238\/arztebl.m2024.0230_ref23","doi-asserted-by":"crossref","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al.: Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024; 391: 109\u201321","DOI":"10.1056\/NEJMoa2403347"},{"key":"10.3238\/arztebl.m2024.0230_ref24","doi-asserted-by":"crossref","unstructured":"McGuire DK, Shih WJ, Cosentino F, et al.: Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type\u00a02 diabetes: a meta-analysis. JAMA Cardiol 2021; 6: 148\u201358","DOI":"10.1001\/jamacardio.2020.4511"},{"key":"10.3238\/arztebl.m2024.0230_ref25","doi-asserted-by":"crossref","unstructured":"Ma C, Li X, Li W, Li Y, Shui F, Zhu P.: The efficacy and safety of SGLT2\u00a0inhibitors in patients with non-diabetic chronic kidney disease: a systematic review and meta-analysis. Int Urol Nephrol 2023; 55: 3167\u201374","DOI":"10.1007\/s11255-023-03586-1"},{"key":"10.3238\/arztebl.m2024.0230_ref26","unstructured":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2018 Consortium: Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 2022; 400: 1788\u20131801"},{"key":"10.3238\/arztebl.m2024.0230_ref27","doi-asserted-by":"crossref","unstructured":"Chen Q, Wang Z, Zhou J, et al.: Effect of urate-lowering therapy on cardiovascular and kidney outcomes: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2020; 15: 1576\u201386","DOI":"10.2215\/CJN.05190420"},{"key":"10.3238\/arztebl.m2024.0230_ref28","unstructured":"Robert Koch-Institut: Empfehlungen der St\u00e4ndigen Impfkommission beim Robert Koch-Institut 2024. Epid Bull 2024; 4: 1\u201372"},{"key":"10.3238\/arztebl.m2024.0230_ref29","unstructured":"Falman A, Sch\u00f6nfeld V, Flasche S, et al.: Beschluss und Wissenschaftliche Begr\u00fcndung zur Empfehlung der STIKO f\u00fcr eine Standardimpfung gegen Erkrankungen durch Respiratorische Synzytial-Viren (RSV) f\u00fcr Personen ≥ 75 Jahre sowie zur Indikationsimpfung von Personen im Alter von 60 bis 74 Jahren mit Risikofaktoren. Epid Bull 2024; 32: 3\u201328"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2024.0230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T11:42:16Z","timestamp":1737632536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2024.0230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":29,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2024.0230","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]}}}